Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant
AssigneeCambridge Biotech Corporation
InventorsGerald A. Beltz, Dante J. Marciani, Chung-Ho Hung, Charlotte A. Kensil
Life of this patent
Estimating the term…
Abstract
The invention relates to antigenic preparations useful for inducing the production of antibodies in a cat which will bind to epitopes on feline leukemia virus. Also disclosed are immunogenic compositions and methods for immunizing a cat to enable the production of antibodies to feline leukemia virus.
Claims9
A vaccine capable of protecting a cat against feline leukemia vira (FeLV) comprising an immunogenically effective amount of FeLV subgroup A recombinant gp70 together with a substantially pure saponin adjuvant selected from the group consisting of QA-7, QA-17, QA-18, and QA-21.
A vaccine capable of protecting a cat against feline leukemia vira (FeLV) comprising an immunogenically effective amount of FeLV subgroup A recombinant gp70-delta together with a substantially pure saponin adjuvant selected from the group consisting of QA-7, QA-17, QA-18, and QA-21.
A vaccine capable of protecting a cat against feline leukemia vira (FeLV) comprising an immunogenically effective amount of FeLV subgroup A recombinant gp90 together with a substantially pure saponin adjuvant selected from the group consisting of QA-7, QA-17, QA-18, and QA-21.
A vaccine capable of protecting a cat against feline leukemia virus (FeLV) comprising an immunogenically effective amount of FeLV subgroup A recombinant gp70-delta together with saponin adjuvant QA-21 and aluminum hydroxide.
Dependencies are inferred from the claim text.